Absorption
The gel matrix absorbs up to 2,500% of its initial weight in blood and remains actively absorbent for up to 24 hours.
FDA Cleared · Rx Only · US Distribution
Four mechanisms of action. One gauze.
WoundClot® Hemostatic Gauze is engineered for the management of mild, moderate and severe bleeding — including in patients on anticoagulant or antiplatelet therapy, and in patients presenting with coagulopathy. Hemovance is your United States distribution partner.
2,500%
Absorption of its own weight in blood
24 hr
Actively absorbent in the wound
4
Distinct mechanisms of action
5 yr
Shelf life from date of manufacture
Mechanism of action
From dry gauze to a 3D gel matrix
On contact with blood, WoundClot® converts from a dry, flexible gauze into a thick, tenacious, expanding three-dimensional gel matrix. That structure is what allows four mechanisms to act at once.
Stage 01 · Applied
Placed dry on the bleeding surface
The dressing goes on dry, directly against the source of bleeding. It can be cut or folded to the wound, and needs no soaking or preparation.
Stage 02 · In contact
Packed under hand weight alone
On contact with blood the gauze begins converting, absorbing up to 2,500% of its weight. No prolonged heavy adjunctive pressure is required.
Stage 03 · Gel matrix
The adherent gel, in situ
The arrow marks the formed matrix: a thick, tenacious gel gripping the wound surface. It stays actively absorbent for up to 24 hours and lifts away without re-bleeding.
Clinical photographs supplied by the manufacturer, Core Scientific Creations Ltd. Individual results vary; these images illustrate use and are not a performance guarantee. A schematic of the underlying mechanism appears on the technology page.
Adhesion
The pliant matrix adheres to surrounding tissue and is not dislodged by patient movement, wound manipulation or high-pressure bleeding.
Aggregation
The matrix concentrates platelets, red blood cells and clotting factors, creating an environment conducive to clot formation.
Activation
Patented functional molecular groups stimulate the coagulation cascade, converting Factors XI and XII to their active forms (XIa, XIIa).
Category difference
The only NONRCS hemostatic in the world
WoundClot® is manufactured from cellulose — a natural plant fiber — using a patented process that leaves the cellulose structure non-oxidized and non-regenerated (NONRCS). Every other cellulose hemostatic on the market is broken down by oxidization, which sharply reduces its capacity to absorb blood, adhere to wound surfaces and sustain an environment conducive to hemostasis.
Because the material is inherently hemostatic, WoundClot® carries no impregnated active ingredient — no kaolin, no chitosan, no collagen, no silica, no thrombin.
- Effective in patients on anticoagulant or antiplatelet therapy — including warfarin, aspirin and heparin
- Effective in patients presenting with coagulopathy
- No prolonged heavy adjunctive pressure required — hand weight or placement pressure is sufficient
- Removed by lifting the clot; re-bleeding does not occur and residual gel irrigates out
- 100% plant-based — no inorganic minerals, shellfish, botanicals, phthalates or latex
- Non-oxidative: does not generate an exothermic reaction or thermal injury
- Does not adhere to gloves or instruments
- Stable and functional from −10 °C to 40 °C, including in low-light, wind and rain
Product lines
Two lines. One technology.
Identical NONRCS material, packaged and sized for two very different environments of care.
WoundClot® Hospital
Operating room, ED & procedural
Six configurations from 2" × 2" pads to an 8" × 12" sheet, including 3" × 8" and 3" × 39" Z-fold. Sterile, peel-open, Rx Only.
WoundClot® EMS
Prehospital, tactical & austere
Four configurations in high-visibility packaging built for rapid identification in a bag or plate carrier, including 3" × 39" Z-fold for wound packing.
Clinical applications
One dressing, every department
Indicated across the full spectrum of bleeding severity, allowing one product to consolidate several SKUs currently stocked separately.
Trauma & emergency surgery
Operative and post-operative hemorrhage control, including high-pressure bleeding.
Orthopedic surgery
Hip, knee and shoulder arthroplasty; spinal fusion; oncologic resection.
Plastic & reconstructive
Donor-site bleeding, flap elevation and broad raw surfaces.
Podiatry & foot / ankle
Nail avulsion, matrixectomy, and procedures in the dysvascular or diabetic foot.
Emergency department
Lacerations, epistaxis, dental avulsion, skin tears and severe extremity hemorrhage.
Chronic wound care
Debridement bleeding, skin tears and fragile peri-wound tissue.
Dialysis & vascular access
AV fistula and graft needle sites, access sites and central venous catheters.
Eight further settings
Cardiology, ENT, dermatology, interventional radiology, oncology, OB/GYN, burns and endoscopic surgery.
Markets served
Where WoundClot® is carried
Hospitals & surgery centers
EMS & fire rescue
Law enforcement
Military
Who we are
Your distribution partner in the lower 48
Hemovance is a growing medical sales representative company and the United States distributor of WoundClot®. We represent one technology, and territory representatives are assigned to an account for its duration: the representative who conducts the in-service remains the point of contact.
We supply evaluation samples, deliver in-service education in the clinical area, and assemble the documentation required by value analysis committees.
Lower 48 coverage
Territory representatives across the contiguous United States.
In-service education
Training on shift, in your department, for the staff who open the package.
Value analysis support
Clearance status, biocompatibility data, literature and cost comparison.
A named contact
One representative is responsible for each account throughout.
Indications for use
WoundClot® Hemostatic Gauze is indicated for the temporary control of mild, moderate and severe external bleeding, and for bleeding at operative, post-operative and donor sites. It is cleared to remain in the wound for up to 24 hours and must be removed prior to closure.
Regulatory status
WoundClot® is FDA cleared and prescription-only in the United States. It is not a US Class III surgical implantable device. In the European Union and other territories it is a CE Class III surgical implantable device in sizes up to 4" × 4". Manufactured by Core Scientific Creations Ltd.
Arrange a clinical evaluation
We supply evaluation samples, in-service education and value-analysis documentation for hospitals, surgery centers, EMS agencies and clinics across the United States.